ISOgenix

Rare genetic diseases affect 350m people worldwide, and many conditions can’t be treated effectively without understanding the full complexity of the proteins that shape them.

ISOgenix is developing precision medicines that harness the power of protein isoforms, alternative versions of proteins produced by RNA splicing, to target neuromuscular and neurological disorders like muscular dystrophy.

Founded by Professors Matthew Wood, Carlo Rinaldi, and Catheryn Lim, the company leverages deep cell and gene therapy expertise to restore function and improve outcomes in patients with limited options today.